Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 3/20 | 0.63 |
| ▸ | CNR2 | P34972 | 11/20 | 0.62 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.58 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29838956 | 0.91 | CNR2 (0.71) | CNR1CNR2 | |
| SCHEMBL923180 | 0.91 | CNR2 (0.71) | CNR1CNR2 | |
| SCHEMBL972368 | 0.90 | CNR1 (0.62) | CNR1CNR2GABRA2GABRB2KDM4E | |
| SCHEMBL923181 | 0.89 | CNR1 (0.61) | CNR1CNR2GABRA2GABRB2KDM4E | |
| SCHEMBL2865960 | 0.89 | CNR1 (0.61) | CNR1CNR2GABRA2GABRB2KDM4E | |
| SCHEMBL17163901 | 0.89 | CNR2 (0.62) | CNR1CNR2GABRA2GABRB2KDM4E | |
| SCHEMBL4193262 | 0.88 | CNR1 (0.60) | CNR1CNR2GABRA2GABRB2 | |
| SCHEMBL17163902 | 0.87 | CNR1 (0.59) | CNR1CNR2GABRA2GABRB2KDM4E | |
| SCHEMBL2221805 | 0.87 | CNR2 (0.62) | CNR1CNR2GABRA2GABRB2KDM4E | |
| SCHEMBL4187487 | 0.87 | CNR1 (0.59) | CNR1CNR2GABRA2GABRB2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7875647-B2 | and inverse agonist; 2-(5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazol-3-yl)-5-(pyridin-4-yl)-1,3,4-oxadiazole; obesity and obesity-related metabolic disorders | GREEN CROSS CORPORATION (KR) | 2011-01-25 | — | — | US | disclosed |
| EP-2097410-A1 | HETEROARYL-PYRAZOLE DERIVATIVES AS CANNABINOID CB1 RECEPTOR ANTAGONISTS | Green Cross Corporation (KR) | 2009-09-09 | — | — | EP | disclosed |
| US-20080081812-A1 | Heteroaryl-Pyrazole Derivatives as Cannabinoid CB1 Receptor Antagonists | GREEN CROSS CORPORATION (KR) | 2008-04-03 | — | — | US | disclosed |
| WO-2008039023-A1 | HETEROARYL-PYRAZOLE DERIVATIVES AS CANNABINOID CB1 RECEPTOR ANTAGONISTS | GREEN CROSS CORPORATION (KR) | 2008-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080081812-A1 | Heteroaryl-Pyrazole Derivatives as Cannabinoid CB1 Receptor Antagonists | CNR2, CNR1, GPR119 | CNR1 2/4885CNR2 1/4885GABRA2 147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.